Table 2.
Hazard ratio of LDL-C and TC dyslipidemia among early-stage breast cancer patients based on endocrine therapy used.
| Menopause | LDL-C | TC | ||||||
|---|---|---|---|---|---|---|---|---|
| Crude HR [95% CI] | P | Adjusted HR* [95% CI] | p | Crude HR [95% CI] | p | Adjusted HR* [95% CI] | p | |
| AI vs. SERM | – | – | – | – | 4.12 [1.90–8.94] | <0.001 | 3.94 [1.81–8.56] | <0.001 |
| ANA vs. TAM | – | – | – | – | 5.58 [2.38–13.04] | <0.001 | 5.32 [2.25–12.55] | <0.001 |
| LET vs. TAM | – | – | – | – | 3.88 [1.60–9.43] | 0.003 | 3.58 [1.47–8.72] | 0.005 |
| ANA vs. LET | 1.30 [0.70–2.41] | 0.407 | 1.09 [0.58–2.06] | 0.782 | 1.44 [0.89–2.33] | 0.135 | 1.41 [0.87–2.29] | 0.164 |
| Pre-menopause | LDL-C | TC | ||||||
| Crude HR [95% CI] | p | Adjusted HR* [95% CI] | p | Crude HR [95% CI] | p | Adjusted HR* [95% CI] | p | |
| OFS+AI vs. SERM | 11.65 [4.70–28.89] | <0.001 | 10.54 [3.86–28.77] | <0.001 | 8.44 [4.53–15.74] | <0.001 | 6.24 [3.19–12.20] | <0.001 |
| OFS+ANA vs. TAM | 15.65 [5.80–42.24] | <0.001 | 15.95 [5.30–48.02] | <0.001 | 8.92 [4.23–18.78] | <0.001 | 6.30 [2.80–14.16] | <0.001 |
| OFS+LET vs. TAM | 6.32 [1.63–24.45] | 0.008 | 6.96 [1.68–28.78] | 0.007 | 9.86 [4.61–21.09] | <0.001 | 8.15 [3.65–18.15] | <0.001 |
SERM, selective estrogen receptor modulator; TAM, tamoxifen; TOR, toremifene; AI, aromatase inhibitor; ANA, anastrozole; LET, letrozole; EXE, exemestane; OFS, ovarian function suppression; TC, total cholesterol; LDL-C, LDL cholesterol; *adjusted for age, BMI, stage, and comorbidity. Refers to the unavailability of computing the HR for no dyslipidemia events occurring among menopausal patients receiving SERM (i.e., TAM).